The House Oversight Committee calls for more FDA action to ensure safe hemp product access
By: Stephanie Ramirez
“It's unfortunate that it's taken this long for Congress to finally get a sit down with the FDA to get the ball really rolling here, but we've had a relatively long leash with CBD.” —Nate Farnsworth, Co-owner, Factory6 Inc.
The Subcommittee on Health Care and Financial Services within the Committee on Oversight and Accountability (U.S. House of Representatives) held a hearing in late July, titled “Hemp in the Modern World: The Yearslong Wait for FDA Action,” to examine the failures of the Food and Drug Administration (FDA) to regulate CBD and hemp-derived products.
The backdrop of this hearing traces back to the pivotal 2018 Farm Bill, which not only ushered in the legality of hemp cultivation and the sale of hemp-derived goods but also affirmed the FDA’s jurisdiction over regulating these products.
Please log in (or register) to continue viewing this content.